Life Sciences

life sciences industry

Today’s life sciences industry faces myriad challenges, including complex regulation, steep competition and ever-changing technologies. Companies around the world turn to Ropes & Gray’s global life sciences group for internationally recognized counsel on virtually all matters impacting their businesses.


“Clients note the team's thorough approach and comprehensive coverage of strategic advisory services and transactional counseling.” Chambers USA
“A fact repeatedly pointed out- the firm maintains a stellar reputation for expertise across regulatory and transactional law.” LMG Life Sciences
“A distinguishing characteristic of Ropes & Gray is the degree to which the firm’s corporate capabilities combine with deep experience in regulatory matters and government investigations. Their team is broad and deep and they have shown a terrific willingness to deliver cost-effective service in unique ways.” LMG Life Sciences


The attorneys and technical specialists who make up the global life sciences group understand the unique needs of a wide range of clients in the dynamic life sciences industry. We work across practices and geographies to develop cutting-edge solutions that help our clients meet their business goals.

In addition to advising biotechnology, pharmaceutical and medical device companies, we also work with:

Drawing on resources in our offices around the globe, we focus on developing cutting-edge solutions to help clients meet their business goals. Our practice includes:


Ropes & Gray’s life sciences team has handled every type of transaction from licensing agreements with a small biotechnology company to large mergers of industry-leading pharmaceutical and medical device companies around the globe. Recent noteworthy transactions include representation of:

  • Pfizer on its $14 billion acquisition of Medivation Inc., a biopharmaceutical company focused on developing and commercializing small molecules for oncology.
  • Shire in its agreement with Baxalta Incorporated to combine the companies for an aggregate consideration of approximately $32 billion. Baxalta, headquartered in Northern Illinois, is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology, and immunology.
  • Boehringer Ingelheim in a $595 million global license and collaboration agreement with AbbVie to jointly develop and commercialize a biologic IL-23 antibody for the treatment of psoriasis and other immunological indications.
  • Vertex Pharmaceuticals in its $2.6 billion strategic research and collaboration agreement with CRISPR Therapeutics.
  • Pacira Pharmaceuticals in First Amendment and APA challenges to FDA’s assertions that the company engaged in “off-label” promotion of its flagship product, a post-surgical analgesic.  As a result, FDA agreed to withdraw its warning letter and revise the label to clarify that the challenged claims were permissible.
  • The Broad Institute of MIT and Harvard in a global licensing agreement with Monsanto Company for the use of the CRISPR-Cas genome-editing technology in agriculture. The agreement is the Broad Institute’s first commercial license for use of the CRISPR technology in agriculture.
  • Pfizer on its definitive agreement to acquire Hospira, an Illinois-based leading provider of injectable drugs and infusion technologies, for approximately $17 billion in the all-cash deal.
  • Novavax Inc., a clinical-stage vaccine company, which focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants, in its $300 million convertible notes offering.
  • Sarepta Therapeutics in its $584 million exclusive license and collaboration agreement with Summit Therapeutics for the European rights to Summit’s utrophin modulator pipeline for the treatment of Duchenne Muscular Dystrophy.
  • Cubist Pharmaceuticals in connection with its $9.5 billion sale to Merck.
  • Wright Medical Technology in its $3.3 billion merger with Tornier NV, creating a new company to be called Wright Medical Group NV, based in the Netherlands. Proteostasis Therapeutics in a $1.2 billion worldwide collaboration deal to develop and commercialize Infinity’s duvelisib for the treatment of patients with cancer.